AstraZeneca ((AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc ((GB:AZN)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca has launched a Phase 1b/2 clinical study titled ‘A Phase 1b/2 Study of AZD0120, a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Refractory Systemic Lupus Erythematosus (SLE).’ The study aims to evaluate the safety, tolerability, and efficacy of AZD0120 in adults with refractory SLE, a condition with limited treatment options.
The intervention being tested is AZD0120, a dual CAR T-cell therapy targeting CD19 and BCMA. This biological treatment is designed to improve outcomes for patients with refractory SLE by modulating immune cell activity.
The study is interventional with a sequential intervention model and no masking, focusing on treatment as the primary purpose. It involves a single-arm, open-label design, where participants receive a single infusion of AZD0120 following lymphodepleting chemotherapy with Cyclophosphamide and Fludarabine.
The study officially started on April 21, 2025, with the latest update submitted on July 15, 2025. These dates are crucial for tracking the study’s progress and assessing its potential impact on treatment paradigms.
The clinical update could positively impact AstraZeneca’s stock performance by showcasing innovation in treating refractory SLE, a challenging autoimmune condition. Investors may view this as a strategic move to strengthen AstraZeneca’s position in the biopharmaceutical market, particularly in immunology.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.